Urocortin 2

Drug Profile

Urocortin 2

Alternative Names: NBI 69734; UCN 2; urocortin II

Latest Information Update: 24 Aug 2015

Price : $50

At a glance

  • Originator Clayton Foundation for Research
  • Developer Neurocrine Biosciences
  • Class Hormones; Peptides; Small molecules
  • Mechanism of Action Corticotropin-releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute heart failure; Alzheimer's disease; Heart failure; Obesity

Most Recent Events

  • 17 May 2012 Pharmacodynamics and adverse events data from a phase I/II trial in Acute decompensated heart failure released by Neurocrine Biosciences
  • 31 Mar 2012 Neurocrine Biosciences completes the phase I/II UNICORN trial in Acute decompensated heart failure in New Zealand
  • 28 Oct 2010 Phase-II clinical trials in Congestive heart failure in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top